Myriad Genetics (MYGN) vs Oruka Therapeutics (ORKA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Oruka Therapeutics (ORKA) has outperformed Myriad Genetics (MYGN) over the past year, gaining 241.6% versus a loss of 45.0%. Over five years, ORKA leads with a +130.8% price change compared with -86.8% for MYGN. Oruka Therapeutics is the larger company by market cap ($5.12 billion vs $401.7 million), about 12.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MYGN | ORKA |
|---|---|---|
| Share price | $4.20 | $77.28 |
| Market cap | $401.73M | $5.12B |
| 1-day change | -1.87% | -2.79% |
| YTD return | -31.71% | +154.97% |
| 1-year return | -45.03% | +241.64% |
| 5-year return | -86.77% | +130.82% |
| EPS (TTM) | $-1.18 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-105.43M |
| 52-week high | $8.59 | $115.52 |
| 52-week low | $2.74 | $24.31 |
| Distance from 52-week high | -51.11% | -33.10% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -6.90% | +100.57% |
| Average volume | 2.02M | 896.59K |
| Shares outstanding | 95.65M | 66.21M |
| Employees | 2,700 | 68 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Oruka Therapeutics is about 12.7 times larger than Myriad Genetics by market value ($5.12B vs $401.73M).
- ORKA has outperformed MYGN by 286.7 percentage points over the past year.
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees
MYGN vs ORKA FAQ
Which is bigger, Myriad Genetics or Oruka Therapeutics?
Oruka Therapeutics (ORKA) is larger, with a market capitalization of $5.12B compared with $401.73M for Myriad Genetics (MYGN).
Which stock has performed better over the past year, MYGN or ORKA?
ORKA returned +241.64% over the past 12 months, compared with -45.03% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Are Myriad Genetics and Oruka Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.